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ABSTRACT
Comprehensive analysis showed that the popularity of research peripheral blood-derived mesenchymal stem cells for knee 
cartilage repair is still lacking, as they peripherally exist at a very low level. Despite its small cell number, peripheral 
blood is yet one of the most convenient sources of mesenchymal stem cells due to its less invasive method to harvest. This 
study aimed to systematically review the current evidence of peripheral blood-derived mesenchymal stem cells towards 
the repair of articular cartilage defect. A comprehensive literature search was performed to identify all in vivo studies 
reporting the structural outcome of articular cartilage repair in the knee following electronic databases: PubMed, WOS 
and SCOPUS. The in vitro characterizations of peripheral blood-derived mesenchymal stem cells were evaluated to enable 
quality assessment. Literature from 1934 to 2019 showed 4822 of total articles with only three findings related to pre-
clinical studies were included in the analysis. The selection of animal model, type of transplantation, mobilization of 
the peripheral blood, in vitro culture condition, type of scaffold, assessments on the cartilage defect, and the outcome 
measures were heterogeneous.  Evidence showed that mobilized peripheral blood-derived mesenchymal stem cells were 
more superior in repairing articular cartilage compared to those that were non-mobilized. These cells also showed a 
comparable capability in repairing articular cartilage than the commonly used bone marrow mesenchymal stem cells. 
Overall, more progress is needed to expand the usage of peripheral blood-derived mesenchymal stem cells from basic 
biological science to the translational studies in clinical practice.
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ABSTRAK
Analisis secara komprehensif menunjukkan bahawa kajian yang berkaitan dengan rawatan lutut yang melibatkan 
penggunaan sel stem mesenkima daripada darah periferal adalah masih pada tahap yang rendah kerana kuantiti sel 
stem tersebut yang amat rendah di dalam darah periferal. Namun begitu, proses memperoleh sel stem mesenkima 
daripada darah periferal adalah mudah kerana ia kurang invasif. Kajian ini adalah bertujuan untuk menyelidik kesemua 
penemuan semasa yang berkaitan dengan sel stem mesenkima daripada darah periferal, yang terlibat dalam meningkatkan 
pemulihan secara in vivo terhadap kerosakan rawan artikul. Carian kepustakaan telah dilakukan secara komprehensif 
dengan menggunakan pangkalan data elektronik seperti: PubMed, WOS dan SCOPUS. Pencirian in vitro untuk sel stem 
ini telah dinilai dalam menentukan tahap kualiti kajian. Kajian kepustakaan bermula dari tahun 1934 sehingga tahun 
2019 menunjukkan bahawa daripada sejumlah 4822 artikel, hanya terdapat tiga kajian pra-klinikal yang berkaitan. 
Setiap kajian melibatkan pelbagai kriteria yang heterogen daripada segi pemilihan model haiwan, jenis transplan, 
kaedah mobilasi darah periferal, kondisi kultur in vitro, jenis rangka (skafold) yang digunakan, tahap kerosakan rawan 
serta kesan pemulihan. Bukti menunjukkan bahawa sel stem mesenkima yang diperoleh daripada darah periferal yang 
telah dimobilasi memiliki kebolehan yang lebih baik dalam memperbaiki rawan artikul berbanding dengan sel stem 
mesenkima yang tidak dimobilasi. Malah, sel ini juga mempunyai keupayaan pembaikian yang setanding dengan sel stem 
mesenkima yang sering diperoleh daripada sumsum tulang. Secara keseluruhannya, penggunaan sel stem mesenkima 
daripada darah periferal perlu diperluaskan lagi bermula daripada bidang asas sains biologi hingga ke kajian translasi 
yang melibatkan pengamalan secara klinikal.
Kata kunci: Darah periferal; osteoartritis lutut; peredaran sel; pre-klinikal; sel stem mesenkima
INTRODUCTION
Articular cartilage of the diarthrodial joints is a connective 
tissue that contains single cellular component, the 
chondrocytes, which are encapsulated in the extracellular 
matrix (ECM) (Sophia et al. 2009). Diffusion of nutrition 
is restricted due to its alymphatic and avascular properties, 
and the small pore size of ECM (~ 6.0 nm) (Linn et al. 
1965; Sophia et al. 2009). Overall, these factors lead to 
slow cartilage metabolism, resulting in poor intrinsic repair 
and healing capacity, which if left untreated will lead to 
osteoarthritis (OA) (Hayes et al. 2001; Jeuken et al. 2016).
Mesenchymal stem cells (MSCs) are the most commonly 
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used source for cell-based therapy for articular cartilage 
repair. MSCs have the potential to differentiate into 
chondrogenic cells, possess anti-inflammatory effect, 
easily expanded in vitro, exhibit homing potential and 
having a wide range of tissue source for harvesting 
(Zachar et al. 2016). Since the discovery by Chonheim et 
al. (1867), bone marrow-derived mesenchymal stem cells 
(BMSCs) have become the touchstone in treating cartilage 
defect (Wakitani 1994). However, harvesting BMSCs is 
painful and invasive, which led to the foundation of the 
minimally invasive source from the peripheral blood that 
promotes fewer complications and lower total cost of the 
transplant procedure that are ideal for clinical application 
(Fu et al. 2013).
 Over the years, peripheral blood mesenchymal stem 
cells (PBMSCs) have gained rather an interest among 
researchers due to its chondrogenic potential. Along with 
PBMSCs, other circulating cells such as peripheral blood 
mononuclear cells (PBMCs) or interchangeably termed as 
peripheral blood progenitor cells (PBPCs) or peripheral 
blood stem cells (PBSCs) have also been rigorously studied 
in vitro and in vivo for cartilage repair (Jansen et al. 2002). 
These circulating cells are isolated from the peripheral 
blood using apheresis, red blood cell lysis buffer and 
density gradient centrifugation to separate the concentrated 
mononuclear cells (MNCs) (Fu et al. 2013). Nevertheless, 
the former is mainly used in clinical practice to obtain 
a large volume of MNCs and is often related to PBPCs or 
PBSCs studies, while the latter two are often applied pre-
clinically from stored blood. These MNCs-rich circulating 
cells do not undergo in vitro cell culture to expand into 
PBMSCs, which render heterogenous population of MNCs 
such as hematopoietic- and mesenchymal stem cells and 
other immature progenitor cells (Chong et al. 2012). 
 PBMCs are mostly used in analyses focusing on in vitro 
studies on chondrogenic potential towards cartilage repair 
(Hopper et al. 2015; Orth et al. 2013). However, PBMCs-
based studies for cartilage repair are often associated 
with partial characterization for MSCs and therefore, did 
not fulfill the standard criteria for MSCs, as stipulated by 
Dominici et al. (2006) in the International Society for 
Cellular Therapy (ISCT) guidelines (Anz et al. 2013; Saw 
et al. 2011). The ISCT categorized MSCs based on their in 
vitro plastic adherence, expressing surface antigens for 
MSCs (cluster of differentiation (CD)73, CD90 and CD105) 
but lack hematopoietic stem cells’ (HSCs’) markers (CD11b 
or CD14, CD19 or CD79a, CD34, CD45 and HLA class II), and 
have the ability to differentiate into at least chondrogenic, 
osteogenic and adipogenic lineages when being induced 
(Dominici et al. 2006). The ISCT criteria were originally 
specified for human MSCs. However, most pre-clinical 
studies used these criteria as a benchmark to characterize 
MSCs in animals, except for the CD markers, which may 
be varied according to species. 
 In this review, we are looking for any potential 
studies involving PB-derived MSCs (PB-MSCs) that promote 
cartilage repair and include a full-characterization of 
MSCs based on the ISCT criteria. Until now, there has been 
no evidence that shows the application of PB-MSCs for 
cartilage repair on the human clinical trial. Therefore, here 
we present a systematic review on publications reporting 
cartilage repair using PB-MSCs such as the pre-clinical 
studies utilizing the purest form of PBMSCs cultivated in 
vitro (Fu et al. 2013; Zhao et al. 2018) or directly utilized 
the heterogeneous PBMC-derived MSCs (PBMC-MSCs) for 
articular treatments on cartilage damage (Hopper et al. 
2015). 
MATERIALS AND METHODS
SEARCH STRATEGY AND STUDY DESIGN
This review was conducted based on the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Liberati et al. 2009) using 
Pubmed, Web of Science (WOS) and SCOPUS databases. 
Two categories of search terms ‘cartilage AND blood AND 
mesenchymal’ and ‘cartilage AND blood AND stem cell’ 
were used. The methods of searching were (All Fields) 
for Pubmed, (Topic) for WOS and (Article Title/Abstract/
Keywords) for SCOPUS. There were no restrictions 
concerning the language and date of publication. All 
searches were deduced by 11th January 2019. Resulted 
articles were critically scrutinized based on the source of 
MSCs from peripheral blood, the characterization of MSCs 
according to the ISCT criteria and its outcome in repairing 
articular cartilage defect in the knee. The references of 
relevant original search were included to support the 
fundamental concept of this literature. 
STUDY SELECTION
Our initial focus was to include the use of PB-MSCs 
for treating defected or damaged articular cartilage in 
animals and humans, particularly in vivo studies at the 
pre-clinical and clinical stages. However, there was 
no evidence of clinical research regarding the usage 
of PB-MSCs. Therefore, only pre-clinical studies were 
included as eligible for the review. The duplicates were 
first excluded from the analysis, followed by any of the 
following categories related to PBMSCs, in vitro studies; 
non-articular cartilage; reviews; systematic reviews 
and non-English articles. Research findings classified 
under PBMCs, PBPCs and PBSCs that did not include any 
ISCT standard criteria for MSCs were further eliminated 
from the list. All of the authors were involved in the 
study selection and data extraction. Any discrepancies 
in viewpoints were resolved by discussions and mutual 
consensus. The flow diagram of the literature search based 
on the PRISMA guideline is depicted in Figure 1.
DATA EXTRACTION AND SYNTHESIS OF FINDINGS
Data from eligible studies were extracted into the evidence 
table. The information includes the name of the authors, 
year of publication, type and number of animals included, 
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location and size of cartilage defects, the treatment 
interventions and the outcome of cartilage repair. The 
ISCT characterization related to cell morphology, surface 
markers, and tri-lineage differentiation, as well as the 
gene expressions and anti-apoptotic ability were also 
extracted. 
RESULTS
STUDY CHARACTERISTICS
Based on the initial search, 4822 articles were identified 
(Figure 1). The earliest journals were listed from 1934 
until 2019 without language restrictions. A total of 2864 
duplicates were excluded. By stratifying PBMSCs, PBMCs, 
PBPCs and PBSCs accordingly, in vitro analyses (n = 19); 
in vivo studies that are not utilizing PBMSCs, for cartilage 
repair (n = 11); systematic review and review (n = 1 each); 
non-English (n = 5) and non-accessible journals (n = 4) 
were eliminated. Exclusions were also applied for articles 
related to MSCs from sources other than peripheral blood 
and those that are not related to MSCs nor cartilage repairing 
studies (n = 1919). 
 The final evaluation resulted in three eligible studies 
for the review, of which two of the studies were focusing on 
PBMSCs, and one finding utilizing what the author claimed 
as PBMC-derived MSCs (PBMC-MSCs). Overall, these studies 
were focusing on the potential of PB-MSCs that adhered 
to the MSCs’ ISCT standard criteria to treat knee articular 
cartilage defects pre-clinically in animal models. 
ISOLATION OF PBMCS AND THE IN VITRO 
CULTURE OF PBMSCS
This review shows that the population of PBMSCs can 
be increased by in vivo and in vitro, before or after the 
isolation of PBMCs. Drug mobilizers were used to increase 
the quantity of PBMSCs in the peripheral blood, which 
allows cultivation in a normoxic culture. Consecutive 
injections of granulocyte colony-stimulating factor (G-CSF) 
and AMD3100 mobilizers were administered in vivo before 
blood withdrawal. Fu et al. (2013) administered a higher 
concentration of G-CSF (50 μg/kg) in their rabbit model, 
compared to 20 μg/kg in the larger animal model using pig 
(Zhao et al. 2018). Subsequently, 5 mg/kg of AMD3100 was 
given in both studies on the 5th day of the final regime. 
Without the mobilizers, PBMCs were instead cultured in 
vitro in a hypoxic condition to increase the adherence and 
colony expansion of PBMSCs (Hopper et al. 2015). 
 To harvest PBMSCs, first, PBMCs were isolated from 
the whole blood. Two of the studies used density gradient 
medium such as lymphoprep of 1.077 g/mL (Hopper et al. 
2015) and 1.131 g/mL (Zhao et al. 2018) to isolate PBMCs 
(Table 1). In contrast, Fu et al. (2013) used erythrocyte 
lysis buffer (ELB) for fast and unperturbed isolation of 
PBMCs, but utilized Ficoll density gradient medium (1.077 
g/mL) to isolate the MNCs from bone marrow (BMCs) for 
positive control. None of the studies mentioned about the 
centrifugal speed and time to isolate PBMCs, except for 
Zhao et al. (2018), with a 25 min centrifugation. While 
maintaining carbon dioxide (CO2) at 5%, most of the 
studies cultured under normoxia (20% oxygen (O2)) to 
FIGURE 1. Flow diagram of literature search
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mimic the oxygen atmospheric air. Hopper et al. (2015) 
showed comparative strategies with enhanced growth and 
proliferation of PBMSCs cultured in hypoxic condition (5% 
O2) compared to those in normoxia. Another significant 
improvement was also shown in the colony formation of 
PBMSCs mobilized by G-CSF combined with AMD3100, 
compared to those mobilized individually by each regime 
(Zhao et al. 2018). 
CHARACTERISTICS OF PBMSCS ACCORDING 
TO THE ISCT CRITERIA
Isolated PBMSCs from the in vitro culture were validated 
according to the standards established by the Mesenchymal 
and Tissue Stem Cell Committee of the ISCT. As the 
fibroblastic morphology itself is part of the five-ISCT 
criteria, other features stipulated under these specifications 
are their ability to: adhere to the culture flask, differentiate 
into the tri-lineage; chondrogenic, osteogenic and 
adipogenic phenotypes, express MSCs surface markers, and 
lack the expression of hematopoietic markers.
 Cultured cells from all three studies were exhibiting 
MSCs characteristics that followed the five-ISCT criteria 
(Table 1). G-CSF-AMD3100 regime indeed mobilized 
PBMSCs, as manifested by the fibroblastic-like morphology 
in the normoxic culture (Fu et al. 2013; Zhao et al. 2018). 
Non-mobilized PBMSCs were able to expand only when 
cultured hypoxically. In normoxia, the culture showed 
only round adherent cells, which was deciphered as 
macrophage (Hopper et al. 2015). In all three studies, the 
most preferably used MSCs surface markers were CD44 and 
CD90, while CD45 was mainly used for HSCs as a negative 
selection for MSCs. 
 The mobilized and normoxic PBMSCs showed 
prominent positivity for CD29 (93.78%) and CD44 (95.14%) 
(Fu et al. 2013), with no significant difference with 
BMSCs, indicating the same epitope profile regardless of 
cell source. Zhao et al. (2018) merely stated the positivity 
for CD29 and CD44 without indicating the intensity of the 
expression profile. Additionally, Zhao et al. (2018) also 
stated the MSCs’ positivity from the mobilized peripheral 
blood, which showed a higher percentage of CD45-CD90+ 
ratio with G-CSF-AMD3100 (9.25%) compared to G-CSF 
(2.15%) and AMD3100 (6.18%), respectively. Unlike Fu 
et al. (2013), the non-mobilized and hypoxic PBMSCs 
showed prominent levels of CD44 (94%) along with other 
MSCs’ CD markers (CD90, CD105, CD106, CD146, CD166, 
Stro-1) (Hopper et al. 2015), which is in contrast with the 
non-mobilized and normoxic PBMSCs that showed weak 
positivity (41%). Each study showed a markedly lack 
expression of MSCs’ negative markers with ≤ 2% positivity.
 This review showed that all studies owned a pronounced 
potentiality in tri-lineage differentiation. Fu et al. (2013) 
performed a comparative study with BMSCs, and it showed 
that PBMSCs manifested a weaker osteogenic potential but 
stronger in adipogenicity and chondrogenicity. The latter 
correlates with the non-mobilized and hypoxic PBMSCs 
based on the increased expression of chondrogenic genes 
in PBMSCs-derived chondrocytes (Hopper et al. 2015). 
Additionally, G-CSF-AMD3100-mobilized PBMSCs exhibited 
a slower proliferation rate compared to BMSCs (Fu et 
al. 2013) but showed a more significant level of colony 
forming unit-fibroblast (CFU-F) than those individually 
mobilized by G-CSF and AMD3100, respectively (Zhao et 
al. 2018).
CHARACTERISTICS OF THE IN VIVO PRE-CLINICAL STUDIES
Table 2 shows the treatment groups of each study that 
primarily involve implantation of a seeded scaffold, which 
was performed right after cartilage defect was created. Two 
studies were seeded with BMSCs as the in vivo standard 
control (Fu et al. 2013; Hopper et al. 2015). Other than 
the non-cultured PBMC-MSCs (Hopper et al. 2015), the 
other two studies used the mobilized and normoxically 
cultured PBMSCs (Fu et al. 2013; Zhao et al. 2015) as the 
seeding cells. To add in more variations, Hopper et al. 
(2015) utilized two combinatorial proportions of 1:2 and 
1:20 for the PBMC-MSCs to BMSCs ratio. Along with these 
were the PBMC-MSCs and BMSCs alone, respectively. It is 
not mentioned by Fu et al. (2013) and Zhao et al. (2018) of 
whether the treatments were allogeneic or autologous. If it 
is allogeneic, there was no information on the age or gender 
of the donor. In contrast, Hopper et al. (2015) were using 
a xenogeneic source of PBMC-MSCs obtained from healthy 
donors, aged 32.9 ± 9.3 years, from both male and female.
TABLE 2. The treatment groups in the in vivo pre-clinical studies
Authors     Fu et al. (2013)     Hopper et al. (2015)*      Zhao et al. (2018)
Treatment
groups
- rPBMSCs/DBM
- rBMSCs/DBM
- DBM
- Empty defect
- hPBMC-MSCs−sBMSCs (1:2)/ 
ChondroMimetic®
- hPBMC-MSCs −sBMSCs (1:20)/ 
ChondroMimetic®
- hPBMC-MSCs /ChondroMimetic® 
- sBMSCs/ChondroMimetic®
- pPBMSCs/BMP2−TGFβ3−chitosan 
microspheres/DBM
- pPBMSCs/BMP2−TGFβ3−chitosan 
microspheres
- DBM
- Empty defect
*Individual treatments using BMSCs and ChondroMimetic were previously performed and showed no significant improvement compared to empty defect. 
Hence, these controls were not repeated to reduce number of animals
DBM = decalcified bone matrix; rPBMSCs = rabbit peripheral blood mesenchymal stem cells; pPBMSCs = pig peripheral blood mesenchymal stem cells; 
hPBMSCs = human peripheral blood mesenchymal stem cells; rBMSCs = rabbit bone marrow mesenchymal stem cells; sBMSCs = sheep bone marrow 
mesenchymal stem cells
1952 
 More details on the in vitro and in vivo parameters 
for PB-MSCs-seeded scaffold are listed in Table 3. Two 
studies implanted natural bone grafts, the decalcified bone 
matrix (DBM) scaffold of the cortical bones of the femur 
(Fu et al. 2013) and scapula (Zhao et al. 2018). The latter 
was fabricated with chitosan microspheres enriched with 
growth factors (BMP2 and TGFβ3) to stimulate healing 
process. A commercially available biological scaffold 
known as the ChondroMimetic® that consists of the 
biphasic collagen-glycosaminoglycan (GAG) was used 
for sheep osteochondral repair (Hopper et al. 2015). This 
synthetic scaffold was seeded with 1 × 106 cells/mL of 
PBMC-MSCs, an amount 100 times lower (2 × 107 cells/mL 
of PBMSCs than being used in the rabbit model with smaller 
osteochondral defect (Fu et al. 2013). Unfortunately, none 
is mentioned in the number of implanted PBMSCs (Zhao et 
al. 2018). 
 Over the years, the animal studies used for PB-MSCs-
based cartilage repair were increasing from small to large 
model. Each study was focusing on different types of 
animal, ranging from small animal using the lapine model 
(New Zealand White rabbit) (Fu et al. 2013) to large animal 
using the ovine model (Welsh Mountain sheep) (Hopper 
et al. 2015) and the porcine model (Diannan small-ear 
pig) (Zhao et al. 2018). These studies showed variation in 
sample sizes; thirty (Fu et al. 2013), twenty-four (Hopper 
et al. 2015) and twelve (Zhao et al. 2018). Two of the 
studies attempted to increase the number of subjects 
(knees) by utilizing bilateral models with single cartilage 
defect on the partial weight bearing area, the trochlear 
groove (Fu et al. 2013), and multiple cartilage defects on 
the high and partial weight bearing area of the medial and 
lateral femoral condyles, respectively (Zhao et al. 2018). 
Meanwhile, Hopper et al. (2015) used a unilateral model 
with a single load-bearing defect on the medial femoral 
condyle only. Focal full-thickness cartilage (Zhao et al. 
2018) and osteochondral defects (Fu et al. 2013; Hopper 
et al. 2015) were created, with the latter penetrating the 
subchondral bone.
OUTCOME OF CARTILAGE REPAIR
The main contexts of the repairing output were mainly 
emphasizing the macro- and microscopic findings 
(Table 4). Fu et al. (2013) proved that there was no 
significant difference in the gross, histological and 
immunohistochemistry findings between cartilage seeded 
with mobilized PBMSCs and BMSCs, respectively. Post-
24 weeks, both MSCs-treatments equally showed the 
development of smooth hyaline cartilage based on the 
abundant expression of proteoglycan, with a close fusion 
between the scaffold and subchondral bone. Meanwhile, 
the non-mobilized PBMC-MSCs and BMSCs showed a 
comparable but reasonably unsatisfactory outcome after 
26-weeks of treatments (Hopper et al. 2015). The safranin 
O-fast green showed more than fifty-percent of healing 
with occasional remnants of the ChondroMimetic® 
scaffold in the osteochondral defects. But overall, there was 
no significant difference in the histological ICRS score and 
gross observation between BMSCs and all PBMC-MSCs-based 
treatments. However, all treatments added with PBMC-MSCs 
showed increased matrix deposition, integration with 
host cartilage hyaline cartilage, and thickness of hyaline 
cartilage. The latter was highest in treatment with PBMC-
MSCs only (62.5%).
 Diversely, mobilized PBMSCs seeded into the BMP2-
TGFβ3 loaded chitosan microspheres/DBM scaffold 
showed the best repairing outcome after 12 weeks (Zhao 
et al. 2018). The gross observation showed full cartilage 
resurfacing of a smooth hyaline-like, with a complete 
integration of the composite scaffold with the lateral 
native cartilage. The histological O’Driscoll score was 20 
out of 24, which is significantly higher than the rest of the 
treatment groups. The col II immunohistochemistry was 
fade but positively stained, which was indistinguishable 
from the native cartilage and the rest of the treatment 
groups.
DISCUSSION 
A comprehensive literature searches of over eight decades 
(since 1934) showed that the application of PBMSCs for 
cartilage repair in the context of in vivo pre-clinical studies 
is still at infancy. Only three articles were found, ranging 
from 2014 - 2018, with PB-MSCs that were characterized 
according to the ISCT standards. Limited number of 
publications signifies the need for more improvements 
to ensure PB-MSCs as one of the promising stem cells for 
cartilage repair. This is most unfortunate since peripheral 
blood provides a direct source of MSCs, and minimally 
invasive compared to the standard BMSCs from the 
bone marrow. The latter requires anaesthesia, multiple 
bone puncturing, and may expose patients to donor-site 
morbidity (Ullah et al. 2015). Our evaluation demonstrates 
that the three studies are relatively contrasting both in 
vitro and in vivo, beginning from the method to cultivate 
PB-MSCs, the size, type and sites of cartilage defects, the 
animal models, the method of cell delivery, and finally to 
the outcome of the cartilage repair. The following segment 
presents an overview of the benefits and limitations of the 
pre-clinical studies using PB-MSCs-based therapy to repair 
focal cartilage defect.
 Countless of clinical studies on repairing cartilage 
have been previously shown using MSCs from various 
sources other than the peripheral blood (Park et al. 2017; 
Vega et al. 2015). This, in turn, shows that there are 
potential limitations that hinder the optimal application 
of PBMSCs in clinical practice. One of the limitations is 
the difficulty to visibly and sufficiently culture PBMSCs 
without the aid of mobilization especially when cultured 
normoxically. It is reported that there is one MSC per 5 × 
103 MNCs of the bone marrow, and this ratio is relatively 
lower in the peripheral blood. In vitro colony formation 
and the expansion of MSCs are density dependence. Thus, 
increasing PBMSCs in the circulation provides sufficient 
amount for in vitro cell-cell communication and hence, 
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cell growth (Hinsenkamp et al. 2014). This review shows 
that the yield of PBMSCs can be magnified not only by 
in vivo, but also by in vitro. In vivo mobilization using 
the combinatorial G-CSF and AMD3100 had increased the 
success rate of culturing PBMSCs by mobilizing MSCs 
from the bone marrow into the peripheral blood (Fu 
et al. 2013; Zhao et al. 2018). Without the aid of these 
mobilizers, there was a weak evidence of PBMSCs in the 
normoxic culture (Hopper et al. 2015; Zhao et al. 2018) 
but PBMSCs showed dominant characterization when 
grown in a hypoxic culture (Hopper et al. 2015). Hypoxia 
in vitro mimics closely the physiologic O2 concentration 
(of 20%) in tissues and organs, including the knee. The 
benefits of hypoxia in vivo reasonably translate into the 
in vitro model in terms of cell growth, proliferation, and 
differentiations. Hypoxia in vitro can selectively lead and 
inhibit the differentiation of certain types of progenitor 
cells (Simon et al. 2008) and thus, the outgrowth of PBMSCs 
from the vast population of progenitor cells in PBMCs.
 This literature shows that both small and large animal 
models were used, theoretically to represent the screening 
study for proof-of-concept (Fu et al. 2013) and pivotal 
study for developmental research, respectively (Hopper 
et al. 2015; Zhao et al. 2018). Defects were created with 
circular shape and within the critical size (diameter) to 
refrain from spontaneous intrinsic repair (Hurtig et al. 
2011). However, several limitations may affect the output 
of cartilage repair. Rabbits are lightweight animals with 
a cartilage that is ~10 times thinner than human, and the 
stifles are normally fully flexed, causing the load bearing 
to being distributed in the lateral compartment of the 
femorotibial joint (Teeple et al. 2013). Therefore, the load 
bearing may not be directly targeted towards the trochlear 
groove of which the osteochondral defect was created 
(Fu et al. 2013). It is presumed to improve the retention 
of the implanted scaffold at the groovy site. However, 
previous studies showed better reparative outcome in the 
trochlea than at the condyles (Orth et al. 2013), as this 
region is partially protected from direct weight bearing 
(Hurtig et al. 2011). In contrast, large animals like sheep 
(Hopper et al. 2015) and pig (Zhao et al. 2018) are more 
closely mimic the human joints. These models owned a 
wider and thicker cartilage, with the load bearing emanate 
mostly in the medial compartment since their knees are 
primarily positioned in full extension (Ahern et al. 2009; 
Hurtig et al. 2011). Owing to this, Hopper et al. (2014) 
created focal defects in the medial femoral condyle, a 
region mostly found in cartilage lesion of osteoarthritic 
patients (Morrey 2011). Zhao et al. (2018) utilized both 
femoral condyles in the medial and lateral, presumably to 
reduce the sample size. But the distinct bearing portion 
and topographic location present a different structural and 
biochemical constitution, which can create variable results 
in cartilage repair (Orth et al. 2013).
 Most of the studies were using a single delivery 
method by directly targeting the defect side with seeded 
using bone grafts (Fu et al. 2013; Zhao et al. 2018) 
or biomaterial (Hopper et al. 2015). These scaffolds 
are categorized as biodegradable, biocompatible, and 
biomimicry with adequate porosity for cell adhesion, 
vascularization, and diffusion of O2, nutrient and 
biofactors (Loh et al. 2013; Xu et al. 2017). The DBM 
graft used by Fu et al. (2013) contains natural source 
of biofactors such as the bone morphogenetic proteins 
(BMPs type 2, 4, 5, 7, 8 and 13), which is useful to 
stimulate both cartilage and bone regeneration) that the 
graft encapsulates. For osteochondral defect, Hopper et 
al. (2015) used a biphasic scaffold (ChondroMimetic®) 
currently used in human in clinical practice, which is 
also that distinctively support the regeneration of both 
cartilage and bone. ChondroMimetic® consists consist 
mainly the type I collagen-GAG biomaterials, which is 
enriched with chondroitin-6-sulfate to mimic the cartilage 
entity, while the calcium phosphate entity is to mimic the 
subchondral bone. On the other hand, Zhao et al. (2018) 
used chitosan microspheres incorporated into the DBM 
scaffold for controlled release of BMP2 and TGFβ3 to 
overcome the growth factors’ short half-lives. The dual 
synergistic effect between these growth factors and the 
naturally released morphogenes from DBM, can lead to 
a prolonged induction of the chondrogenic potential of 
PBMSCs (Wan et al. 2014). Besides, these growth factors 
can selectively induce the osteogenic potential of MSCs 
depending on the vascularity of the repair site, particularly 
the O2 accessibility (Hinsenkamp et al. 2014), and thus, 
suitable for both cartilage and osteochondral repair. 
 Several clinical results showed limited success 
with ChondroMimetic®, either with or without cell 
infiltration (Tamaddon et al. 2018). However, previous 
translational study using sheep model has shown that 
ChondroMimetic® combined with recombinant human 
fibroblast growth factor (rhFGF18) showed more 
significant repairing outcome in the osteochondral defect 
compared to when combined with BMP7 (Getgood et 
al. 2014). This study shows that the reparative outcome 
depends on the type of infiltrated materials. It is 
concluded, and as aforementioned in this discussion, that 
the non-mobilized PBMSCs were evidently insufficient 
to repair the large cartilage defect. Culturing in hypoxia 
did not effectively increase the number of PBMSCs. The 
interpretation of the macroscopic and histological outcome 
was however, not correlative and slightly confusing. 
Some of the samples demonstrated closure of defect that 
showed hyaline-like cartilage. However, the rest of the 
defect was not macroscopically and histologically fully 
matured, with scaffold still apparent based on the non-
uniform opacity and incomplete fusion of the cartilage. 
The ICRS macroscopic score was also exhibiting just nearly 
normal cartilage repair (Grade II) (van den Borne et al. 
2007). Ironically, the overall phenomenon showed that 
PBMSCs exhibit better formation of hyaline-like cartilage 
than BMSCs, which was opposed to Fu et al. (2013) where 
both sources of MSCs were equally capable in producing 
hyaline-like cartilage construct, with similar macroscopic 
and histological outcome. It is unclear why both studies 
presented different repairing superiority since Fu et al. 
1956 
(2013) and Hopper et al. (2013) transplanted equal number 
of PBMSCs and BMSCs to their research. It could be that 
the autologous rabbit MSCs (Fu et al. 2013) owned better 
congruity and therefore, better regenerative effect on their 
own physiological system compared to using xenogeneic 
MSCs from human (Hopper et al. 2015). Nevertheless, 
the reparative outcome was not parallel with the in vitro 
results. The chondrogenecity was stronger in PBMSCs but 
was slower in the growth rate (Fu et al. 2013). Therefore, 
it is evident that further investigation is needed to proof 
and correlate the argument mentioned before.
 There are several limitations that we found on the pre-
clinical data. For instance, the exclusion of the amount of 
seeded PBMSCs used in the scaffold (Zhao et al. 2018) along 
with the passage number (Fu et al. 2013). This renders the 
difficulty to evaluate the reparative effect of PB-MSCs, and 
for future reference in cartilage regeneration, as higher 
passage number may significantly reduce the efficacy of 
MSCs to differentiate into chondrogenic cells (Jiang et al. 
2017). On the other hand, based on the available data, 
Hopper et al. (2015) seeded a 100 times lesser amount of 
cells compared to Fu et al. (2013). Previous pre-clinical 
studies on large animals have shown that the number 
of seeded or transplanted MSCs was increased in larger 
cartilage or osteochodral defects, ranging from 1 × 107 
to 3.8 × 107 in sheep and pig, respectively (Bornes et al. 
2018; Nakamura et al. 2012). Based on these findings, it 
proves that Hopper et al. (2015) seeded a low number of 
PBMC-MSCs (1 × 106) that led to a less sufficient reparative 
outcome in the osteochondral defect, while Fu et al. (2013) 
were utilizing a therapeutic amount of PBMSCs exceeding 
the normally used range of 5 × 106 (Jia et al. 2018), which 
is more than sufficient for small osteochondral defect.
 Based on our observation, the number of sample size 
is decreasing from smaller to larger animals apparently to 
lower down the cost due to the increasing complexity of 
handling. Fu et al. (2013) and Zhao et al. (2018) performed 
a staggering time points up to 3 months, a short duration 
mainly to examine the repair and failure mechanisms 
of scaffold implantation to refine the repairing method 
and cell dose-response. Often at this early stage, the 
repairing level is still immature for large animal (Hurtig 
et al. 2011). But the reparative outcome in the pig model 
(Zhao et al. 2018) was better compared to the sheep 
model (Hopper et al. 2015). As aforementioned, although 
the number of PBMSCs was not mentioned by Zhao et al. 
(2018), yet, it is most likely due to the sufficient amount 
of MSCs transplantation. Like Fu et al. (2013), Hopper 
et al. (2015) prolonged the treatment to 6 months. This 
healing duration is more crucial for pivotal study (Hurtig 
et al. 2011), and it is the minimal time point to evaluate 
the maturation of cartilage repair. Based on this data, it 
is suggested that prolonged treatment duration of up to a 
year or more (Hurtig et al. 2011), or increasing the number 
of transplanted PBMSCs would be required to improve 
the output of cartilage repair. All of the animal studies 
proclaimed of using age that falls within the skeletally 
matured range to avoid the intrinsic spontaneous healing 
(Teeple et al. 2013). However, Zhao et al. (2018) did not 
mention on the age used for the adult pigs. According to 
a previous study, 8 months-old diannan small-ear pig was 
used for focal cartilage repair (Wang et al. 2014). However, 
1 - 3 years is mostly the adult range for varying breeds of 
pigs (Nakamura et al. 2012). 
CONCLUSION
Overall, Fu et al. (2013) showed the best cartilage 
repair followed by Hopper et al. (2015) and Zhao et al. 
(2018). Hopper et al. (2015) has the biggest dimension of 
defect in the full-weight bearing region (medial femoral 
codyle), and hence, require a higher number of PBMSCs 
for best reparative outcome. Fu et al. (2013) has the 
advantage of owing the smallest defect dimension that 
confined in the partial bearing area (trochlear groove), 
having the highest number of transplanted PBMSCs 
along with a considerably long treatment duration for 
small animal model (rabbit). For Zhao et al. (2018), the 
number of transplanted PBMSCs is unknown. However, 
as aforementioned, it is presumably within the optimal 
range for therapeutic efficiency. Zhao et al. (2018) has 
the best animal model (pig) that not only mimic closely 
to human, but also has the thickest and widest cartilage 
that allows the utilization of all the condyles in both 
knees. Compared to hypoxic culture, the potentiality 
of mobilized PBMSCs to provide good reparative output 
indicates the robustness of using mobilization to gain a 
high number of PBMSCs. Nevertheless, other than PBMSCs, 
the infiltrated components infused into the scaffold 
also play the important role in enhancing the cartilage 
reparative effect by.
 Through our comprehensive review of both 
studies, it is evident that PB-MSCs have high potential in 
regenerating cartilage defect. The major drawback that 
we have excerpted is the need to add inducers to improve 
and increase the quantity of PBMSCs. Although hypoxia 
can be applied in vitro, the relative number of PBMSCs 
is still lower compared to the commercially available 
drug, G-CSF. Both utilize different concepts of inducer; 
by increasing cell proliferation (hypoxia in vitro) and 
by mobilizing MSCs into the peripheral blood (in vivo). 
Although G-SCF showed far better outcome, its side 
effects must be well considered, despite being clinically 
approved and commonly used in the clinical practice. 
On the experimental aspect, both studies showed that 
PBMSCs were able to survive in vitro expansion both in 
normoxic and hypoxic conditions. Although the reparative 
outcome between PBMSCs and BMSCs were comparable, 
this finding was relatively inconsistent due to the different 
experimental parameters applied in both studies, rendering 
direct comparison somewhat challenging. Nevertheless, 
it is evident that PBMSCs have full potential in repairing 
cartilage defect pre-clinically and therefore, could be 
the next favorable source for regenerative medicine in 
cartilage repair for clinical practice.
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